niraparib and Cystadenocarcinoma--Serous

niraparib has been researched along with Cystadenocarcinoma--Serous* in 2 studies

Other Studies

2 other study(ies) available for niraparib and Cystadenocarcinoma--Serous

ArticleYear
Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases.
    BMJ case reports, 2019, Aug-28, Volume: 12, Issue:8

    Ovarian cancer is the second the most common gynaecological malignancy in developed countries. 70% of patients relapse in the first 3 years following debulking surgery and first-line chemotherapy. Niraparib is a poly adenosine diphosphate ribose polymerase inhibitor which uses the concept of synthetic lethality in the presence of a mutation in the breast cancer susceptibility gene (

    Topics: Aged; Brain Neoplasms; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Treatment Outcome

2019
Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.
    The New England journal of medicine, 2019, 12-19, Volume: 381, Issue:25

    Topics: Cystadenocarcinoma, Serous; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Precision Medicine

2019